Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$35.8MCash on Hand
14.7mo Cash Runway
Follow COYA by emailGet an email when COYA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about COYA, unsubscribe in one click. Privacy
📣 What COYA Says Is Next
Q2 2027 · COYA 302: ““With topline data anticipated in early Q2 2027, we remain focused on communicating data from this study as soon as it is available.” Recent Corporate Highlights”
Company press release, Nov 10, 2026 · SEC filing
second half of 2027 · COYA 302: “The Company’s cash runway guidance remains unchanged, with existing cash resources expected to fund operations into the second half of 2027, beyond the anticipated ALSTARS topline data readout.”
Company press release, Oct 14, 2026 · SEC filing
second half of 2026 · COYA 302: “With this prioritization, the planned initiation of the Phase 2 clinical trial evaluating COYA 302 in frontotemporal dementia (“FTD”), previously anticipated in the second half of 2026, is now expected in 2027.”
Company press release, Oct 14, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 10, 2026 ·
Earnings Reported Q3 2026 net loss of $10.6 million versus $2.1 million a year earlier, with R&D expenses rising to $8.6 million from $2.9 million on the COYA 302 ALS trial. Cash and equivalents were $35.8 million, which the company says funds operations past ALSTARS topline data in early Q2 2027. Form 8-K · SEC filing · Press release
Nov 10, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 14, 2026 ·
Clinical trial Coya plans an open-label extension of its ALSTARS Phase 2/3 trial of COYA 302 in ALS, starting November 2026, and has delayed the planned FTD Phase 2 trial start from the second half of 2026 to 2027. Cash runway into the second half of 2027 is unchanged. Form 8-K · SEC filing
Oct 5, 2026 ·
Clinical trial Announced full enrollment of 120 patients in the Phase 2/3 ALSTARS trial of COYA 302, a combination of low-dose IL-2 and CTLA-4 Ig, for ALS. Topline double-blind data are expected in early Q2 2027, with the primary endpoint the change in ALSFRS-R score at Week 24 versus placebo. Form 8-K · SEC filing
Sep 15, 2026 ·
Clinical trial Enrollment of the 100th patient in the Phase 2/3 ALSTARS trial of COYA 302 for ALS was announced. The company expects to enroll all 120 participants in time to report topline data in early Q2 2027. Form 8-K · SEC filing
Aug 11, 2026 ·
Earnings Reported Q2 2026 net loss of $6.6 million versus $6.1 million a year earlier, with R&D expenses rising to $5.0 million and cash of $43.2 million. Company says cash funds operations past the ALSTARS topline readout into 2H 2027. Form 8-K · SEC filing · Press release
Aug 11, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Apr 2027 · Phase 2/3 · Active Trial · Study of COYA 302 for the Treatment of ALS Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
COYA holds $35.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $7.3M/quarter from operations,
an estimated runway of 14.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:65 · High
Cash runway 15 months +18
ATM program on file since May 2026 +15
Shelf registration (S-3, Aug 2025) +10
Going-concern doubt in the latest 10-Q +15We are a clinical stage biotechnology company and have incurred significant losses since our inception, and we expect to incur losses for the foreseeable future, which raises substantial doubt about our ability to continue as a going concern.10-Q, Nov 2026
Share count 23,457,849 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full COYA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for COYA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.